Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

This study is testing a new type of immune cell therapy called CD19x22 CAR T cells — immune cells re-engineered to attack two targets on cancer cells at once — for people with B-cell blood cancers that have come back or stopped responding to prior treatments. **You may be eligible if...** - You are 16 years or older (first three participants must be 18+) - You have aggressive B-cell lymphoma (such as Diffuse Large B-Cell Lymphoma) that has relapsed or is treatment-resistant, OR B-cell cancer that has spread to the brain or spinal cord - You have received prior standard treatments that have not worked **You may NOT be eligible if...** - You have signs of active, uncontrolled disease in the central nervous system (for non-CNS group) - You have serious heart, lung, or kidney problems that could prevent safe treatment - You are pregnant or breastfeeding - Your blood counts are too low to safely undergo the therapy Talk to your doctor to see if this trial is right for you.